Spectral AI Will Present DeepView System at ACS Congress
The company will demonstrate its FDA-cleared AI burn assessment tool for surgeons in Washington this September.
Updated on Sept. 24, 2026 in Artificial Intelligence
Live Poll
Do you trust artificial intelligence to improve the accuracy and speed of medical diagnostic tests?
Dallas-based Spectral AI will present its DeepView System at the ACS Clinical Congress 2026, scheduled for September 26-29, 2026. The company intends to increase awareness of the technology among surgeons beyond the burn specialty following its FDA De Novo classification in May 2026.
Why it matters
The DeepView System aims to standardize the assessment of burn wounds by predicting healing outcomes within a 21-day window. This development helps bridge the gap between specialized burn care and broader surgical practices by automating complex diagnostic tasks.
The system relies on a database of over 340 billion pixels of burn wound data. It achieves a total workflow cycle of approximately 20 to 25 seconds, consisting of 0.2 seconds for image acquisition and the remaining time for algorithmic processing.
The players
Spectral AI
A Dallas-based company developing predictive AI systems for clinical burn wound diagnostics.
James H. Holmes IV
The physician lead responsible for presenting the clinical device at the ACS Congress.
The details
The DeepView System combines multispectral imaging—a technique that captures image data across specific electromagnetic frequencies—with a proprietary AI algorithm to analyze wound tissue. By processing these images, the software assesses whether a burn wound is unlikely to heal within 21 days. This quantitative assessment replaces traditional subjective visual inspections with data-driven predictions.
Timeline
February 2024: DeepView System received UKCA authorization.
May 2026: DeepView System granted FDA De Novo Classification.
September 24, 2026: Spectral AI announced the upcoming conference presentation.
September 26-29, 2026: ACS Clinical Congress 2026 takes place in Washington, DC.
The Tech Race
The presentation at the ACS Clinical Congress 2026 marks a strategic shift to expand the user base for AI-driven surgical diagnostics beyond the established burn care community. Spectral AI is currently working to build market share following its 2025 recognition by TIME as a top health-tech firm.
Surgeons attending the September congress will receive a technical overview of the device's diagnostic capabilities. Availability and widespread adoption for clinicians will depend on further integration into hospital workflows following the FDA clearance.
The takeaway
This presentation underscores the push toward bringing automated, objective diagnostics into general surgical settings. Observers should track the reception among attendees at the upcoming ACS Congress as a barometer for broader clinical adoption.
Further reading
For more on the latest developments in diagnostic tools, visit Artificial Intelligence.
More information
Review technical details on the Spectral AI company information portal.
Live Poll
Do you trust artificial intelligence to improve the accuracy and speed of medical diagnostic tests?
